Hopitaux Universitaires de Genève
Geneva, 1205, Switzerland
Location status: Recruiting
Location contact
Pr Valentina Garibotto Head of Nuclear Medecine and molecular imaging
CONTACT
Valentina Garibotto
PRINCIPAL_INVESTIGATOR
NCT Number: NCT07006155
The main purpose is to evaluate initial clinical experiences and to explore whether the Vision.X system yields improved image quality and diagnostic performance compared to Vision 600.
Interested in participating?
Request Info18 year–85 year
All sexes
Interventional
Not applicable
Geneva, 1205, Switzerland
Location status: Recruiting
Pr Valentina Garibotto Head of Nuclear Medecine and molecular imaging
CONTACT
Valentina Garibotto
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
PET/CT images
Time frame: through study completion , an average of 1 year
The primary outcome will be image quality assessed on the two compared PET systems, namely Vision and Vision X.
For the all PET scans, three independent, blinded physicians will evaluate the scans and establish diagnoses. They will assess the following quality criteria using 5-point Likert scales:
Time frame: through study completion , an average of 1 year
The secondary outcome will be the assessment of image quality (as for the primary outcome) on simulated lower doses of radiotracer activity on both PET systems (Vision and Vision X).
To assess this, the same parameters described in section 5.1 will be evaluated across different emulated scan times, as shorter scanning times allow simulating lower administered activities. These will be generated by binning the list-mode data with varying frame durations for both scanner acquisitions.
The lowering of the radiotracer activity maintaining a high-quality image is relevant for its capacity to reduce the radiation exposure for the patients and contributes to optimizing healthcare resources.
Contact information is provided by the study sponsor or research team.
Pr Valentina Garibotto Head of the Division of nuclear medicine and molecular imaging, MD
CONTACT
Valentina Garibotto
Other
Intra-individual Comparison of PET Scans on the Biograph Vision 600 With the New Biograph Vision.X PET/CT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02108769
Alzheimer Disease, Brain Diseases
Charleston, South Carolina, United States
View Trial DetailsNCT06923501
Alzheimer Disease, Brain Diseases
New Haven, Connecticut, United States
View Trial DetailsNCT05315895
Aging, Alzheimer Disease
Guangzhou, Guangdong, China
View Trial DetailsNCT07205978
Alzheimer Disease, Basal Ganglia Diseases
Copenhagen, Denmark
View Trial Details